NCT01529294

Single-dose Iloperidone Pharmacokinetics in Patients With Mild or Moderate Liver Disease, Compared to Healthy Volunteers

Open-label, Single-dose, Parallel-group Study to Compare the PKs of Iloperidone in Subjects With Mild or Moderate Hepatic Impairment With That in Matched Healthy Control Subjects

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 90 (actual)
• Sponsor: Novartis Pharmaceuticals · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Accepted

Summary

This study aims to determine the pharmacokinetic profile and the tolerability of iloperidone in subjects with mild or moderate hepatic impairment comparatively to healthy matched subjects

Conditions

• Hepatic Impairment

Interventions

Type	Name	Description
DRUG	Iloperidone

Timeline

• Start date: 2010-08-01
• Primary completion: 2012-07-01
• Completion: 2012-07-01
• First posted: 2012-02-08
• Last updated: 2013-03-14

Locations

4 sites across 1 country: United States